Fig. 5.

HDAC6 inhibition protects against LPS-induced EBD. A: HLMVEC were grown in 100-mm dishes. When confluent, the cells were treated with either PBS or LPS (1 EU/ml) for 2 h. Cells were then lysed, HDAC6 was immunoprecipitated, and HDAC activity was measured using the Flour-de-lys HDAC activity assay. B and C: HLMVEC were grown in 100-mm dishes. When confluent, the cells were treated with the indicated concentrations of the HDAC6-selective inhibitor tubastatin for 2 h, and total HDAC (B) and HDAC6 (C) activity were measured, as described previously. *P < 0.05 from vehicle; n = 4. D: HLMVEC were grown to confluence on ECIS arrays (8W10E+). Once a constant resistance was attained, the cells were treated with either vehicle (0.1% DMSO) or 5 μM tubastatin (Tub) for 2 h. LPS (1 EU/ml) was then added as indicated, and TER values were measured using ECIS Zθ. *P < 0.01 from vehicle. #P < 0.05 from LPS.